Immunogenicity

Immunogenicity is the tendency of a therapeutic to provoke an immune response to itself, most consequentially anti-drug antibodies. Risk is set by four groups of factors. Product factors include how far the sequence departs from human, aggregates and particles, glycosylation, host cell protein and container leachables. Process factors include buffer composition, surfactant, agitation history and freeze-thaw exposure. Treatment factors include route and schedule, with subcutaneous intermittent dosing generally more immunogenic than continuous intravenous infusion.

Aggregation is the dominant modifiable driver, since repetitive epitope arrays can activate B cells without T cell help, which is why regulators require aggregate control across shelf life and a risk-based assessment rather than a single assay result. The instructive case is the epoetin alfa formulation change of the late 1990s, after which a cluster of antibody-mediated pure red cell aplasia appeared in Europe, traced to product and container changes rather than the sequence. Short synthetic peptides are less immunogenic than full proteins but not exempt: salmon calcitonin, a thirty-two residue non-human sequence, raises antibodies in a substantial fraction of chronically treated patients.

Because the drivers are physical as much as molecular, immunogenicity is partly a handling problem. The same molecule, aggregated by shaking, warm storage or repeated freeze-thaw, presents a different immunological object than the intact monomer.

The misreading worth naming concerns purity certificates. Chromatographic purity is measured across a monomer peak and says nothing about aggregate content, which needs size-exclusion or light-scattering methods that grey-market documents never include. A ninety-nine percent purity figure is silent on the single largest immunogenicity driver.